Granules has received marketing approval from the US Food and Drug Administration (USFDA) for Potassium Chloride extended release tablets USP in the strengths of 10 mEq (750 mg) and 20 mEq (1500 ...

Camber's potassium chloride extended-release tablets are used to prevent or treat low blood levels of potassium (hypokalemia). ... (750 mg) 10 mEq K and (1500 mg) 20 mEq K strengths.

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq ...

The Food and Drug Administration approved Glenmark Pharamceuticals' potassium chloride tablets. The tablets, used to treat a potassium deficiency, are a generic version of K Dur tablets produced ...

Citing IQVIA Health data, Granules said Potassium Chloride extended release tablets had US generic sales of approximately USD 204 million for the most recent 12 months ending in August 2020.

“Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq ...

Glenmark Pharmaceuticals has received final approval from the US health regulator for Potassium Chloride Extended Release Tablets, used for treating low levels of potassium in blood. “Glenmark ...

Company's current portfolio consists of 117 products authorised for distribution in the US marketplace and 61 ANDA pending approval with the USFDA.